Panorama 2 is a multi-national, multi-center, prospective, non-randomized, post-market, observational registry conducted in various regions across the world

PANORAMA 2, Medtronic CRDM Implantable Cardiac Device Long Term Registry - Panorama 2

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2013/03/003464

Enrollment

8500

Registered

2013-03-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with arrthymias and eligible for an implant of any CRDM therapy

Interventions

Intervention1: Not applicable: Not applicable Intervention2: There is no intervention in this study.: Patients receiving therapy from an eligible product, i.e all commercially available implantable Me

Eligibility

Inclusion criteria

Inclusion criteria: • Patient is 18 years of age or older (lower age limit dependent on local law: to be specified in country-specific addendum to the clinical investigational plan, if applicable) • Patient or Legally Authorized Representative provides signed and dated authorization and/or consent per institution and local requirements • Patient will be treated with a commercially available implantable Medtronic CRDM device/Vitatron device within maximally 30 days after enrollment or within 3 days prior to enrollment

Exclusion criteria

Exclusion criteria: • Patient has exclusion criteria per local law (to be specified in country-specific addendum to the clinical investigational plan, if applicable)

Design outcomes

Primary

Measure	Time frame
To describe the region-specific current clinical practices associated with the device treatment of patients receiving implantable Medtronic CRDM devices by collecting information on the patient characteristics (demographics, medical history and cardiovascular status), the type of Medtronic CRDM devices used, the indication for the use of the Medtronic CRDM devices and the clinical outcomes of the treatment with the Medtronic CRDM devicesTimepoint: Minimum 1 year post implant and maximum 5 years post implant	—

Measure

Time frame

To describe the region-specific current clinical practices associated with the device treatment of patients receiving implantable Medtronic CRDM devices by collecting information on the patient characteristics (demographics, medical history and cardiovascular status), the type of Medtronic CRDM devices used, the indication for the use of the Medtronic CRDM devices and the clinical outcomes of the treatment with the Medtronic CRDM devicesTimepoint: Minimum 1 year post implant and maximum 5 years post implant

—

Secondary

Measure	Time frame
To collect region-specific data on product reliability (Serious Adverse Device Effects, device related deaths and device related cardiovascular hospitalizations) of implantable Medtronic CRDM devicesTimepoint: Minimum 1 year post implant and maximum 5 years post implant	—

Countries

Bangladesh, Brazil, India, South Africa

Contacts

Public ContactRajesh Radhakrishnan

India Medtronic Pvt Ltd

rajesh.radhakrishnan@medtronic.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026